2,588 Elevance Health, Inc. $ELV Shares Bought by North Dakota State Investment Board

North Dakota State Investment Board increased its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 39.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 9,203 shares of the company’s stock after purchasing an additional 2,588 shares during the period. North Dakota State Investment Board’s holdings in Elevance Health were worth $3,578,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. VestGen Advisors LLC boosted its holdings in shares of Elevance Health by 92.5% in the 3rd quarter. VestGen Advisors LLC now owns 1,211 shares of the company’s stock valued at $471,000 after purchasing an additional 582 shares in the last quarter. Asset Management One Co. Ltd. raised its holdings in shares of Elevance Health by 0.7% during the 3rd quarter. Asset Management One Co. Ltd. now owns 100,029 shares of the company’s stock worth $38,893,000 after buying an additional 708 shares in the last quarter. SYM FINANCIAL Corp raised its holdings in shares of Elevance Health by 37.5% during the 3rd quarter. SYM FINANCIAL Corp now owns 943 shares of the company’s stock worth $367,000 after buying an additional 257 shares in the last quarter. Angeles Wealth Management LLC acquired a new position in shares of Elevance Health during the 3rd quarter worth $275,000. Finally, Apollon Wealth Management LLC lifted its position in shares of Elevance Health by 7.8% during the 3rd quarter. Apollon Wealth Management LLC now owns 4,328 shares of the company’s stock worth $1,683,000 after buying an additional 314 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

NYSE ELV opened at $413.42 on Thursday. The firm’s fifty day moving average price is $409.71 and its two-hundred day moving average price is $371.85. The stock has a market cap of $89.32 billion, a PE ratio of 17.63, a PEG ratio of 2.10 and a beta of 0.70. Elevance Health, Inc. has a fifty-two week low of $274.84 and a fifty-two week high of $450.69. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47.

Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. During the same period in the prior year, the business earned $6.03 earnings per share. The company’s revenue for the quarter was up .7% compared to the same quarter last year. On average, equities analysts expect that Elevance Health, Inc. will post 29.15 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a dividend of $1.72 per share. The ex-dividend date is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is currently 29.34%.

Analyst Ratings Changes

ELV has been the topic of several research analyst reports. Leerink Partners raised their price objective on Elevance Health from $364.00 to $395.00 and gave the company a “market perform” rating in a research note on Friday, July 17th. Robert W. Baird lifted their target price on Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a research report on Thursday, October 22nd. Morgan Stanley boosted their target price on Elevance Health from $404.00 to $449.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 22nd. Mizuho set a $490.00 target price on shares of Elevance Health in a report on Friday, October 23rd. Finally, Wells Fargo & Company increased their target price on shares of Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a report on Tuesday. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $456.48.

Read Our Latest Research Report on ELV

Insiders Place Their Bets

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. This represents a 34.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is owned by corporate insiders.

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.

Recommended Stories

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.